Low Dose Aspirin Studied With the AggreGuide
This study has been completed.
Sponsor:
Edward R. Teitel, M.D.
Information provided by (Responsible Party):
Edward R. Teitel, M.D., Aggredyne, Inc.
ClinicalTrials.gov Identifier:
NCT01603966
First received: May 21, 2012
Last updated: July 14, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is to determine whether the AggreGuide platelet aggregometer can discern the effect of low dose aspirin on subjects platelet aggregation using arachidonic acid as the agonist.
| Condition |
|---|
|
Platelet Aggregation |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Crossover Time Perspective: Prospective |
| Official Title: | Low Dose Aspirin Study With the AggreGuide |
Resource links provided by NLM:
Further study details as provided by Aggredyne, Inc.:
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
community sample
Criteria
Inclusion Criteria:
- adults
Exclusion Criteria:
- aspirin contraindications
- anticoagulants
- aspirin past week
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Edward R. Teitel, M.D., CEO, Aggredyne, Inc. |
| ClinicalTrials.gov Identifier: | NCT01603966 History of Changes |
| Other Study ID Numbers: | Val-030 |
| Study First Received: | May 21, 2012 |
| Last Updated: | July 14, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Aggredyne, Inc.:
|
platelet aggregation aspirin inhibition reactivity |
Additional relevant MeSH terms:
|
Aspirin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents |
Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents Hematologic Agents Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics Central Nervous System Agents |
ClinicalTrials.gov processed this record on June 18, 2013